Opthea Limited has published its 2024-2025 Annual Report, highlighting significant developments over the past year. The report marks a turning point for the company, with a focus on leveraging scientific understanding of VEGF-C and D biology to develop innovative medicines. Despite promising Phase 2 data, the company's two Phase 3 clinical trials, COAST and ShORe, evaluating sozinibercept (OPT-302) for the treatment of wet age-related macular degeneration, did not meet their primary and secondary endpoints. This outcome has led Opthea to enter cash preservation mode, resulting in a reduction of its team and several Board members stepping down. The company's management reaffirms its commitment to supporting and growing innovations originating in Australia, while acknowledging the heightened risks in the biotech sector. The full report can be accessed through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opthea Limited published the original content used to generate this news brief on September 15, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.